None
Quote | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)
Last: | $0.425 |
---|---|
Change Percent: | 12.01% |
Open: | $0.4768 |
Close: | $0.425 |
High: | $0.51 |
Low: | $0.42 |
Volume: | 366,686 |
Last Trade Date Time: | 01/17/2023 03:40:41 pm |
News | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)
Rare-disease-focused nano-cap biotech Idera Pharmaceuticals ( NASDAQ: IDRA ) fell ~22% on Tuesday after the company said that a 1-for-17 reverse stock split of its common stock would take effect when the market opens on January 18, 2023. Concurrently, Exton, Pennsylvania-based Ide...
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
Message Board Posts | Idera Pharmaceuticals Inc. (NASDAQ:IDRA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $ACGN 87% v16,0M c3.11 f8,423M H5.37 ML1.51 | znewcar1 | investorshangout | 05/04/2023 3:38:30 AM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 04/30/2023 9:21:14 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 04/15/2023 3:35:21 PM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 02/27/2023 12:32:32 AM |
$IDRA Idera Pharmaceuticals Inc | mick | investorshub | 02/21/2023 10:41:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...